CClinicalTrials.gg
Not yet recruitingNCT06098677Updated Jan 23, 2026

Effect of Carotenoids Supplementation on Visual Function in Chinese Subjects

An interventional study of Carotenoids supplementation and Placebo in Vision Disorders, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Not yet recruiting. Open to participants aged 35 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Study summary

The macula is a pigmented area at the center of the retina, and responsible for the central, high-resolution color vision. Age-related macular degeneration (AMD) is a disease of the macula and is the leading cause of irreversible vision impairment and blindness worldwide. The yellow pigment at the macula is referred to as macular pigment. There is now strong evidence showing that macular pigment (MP), which is composed of the dietary carotenoids lutein (L), meso-zeaxanthin (MZ), and zeaxanthin (Z) is protective against AMD and vision loss. MP is a powerful antioxidant and also filters short-wavelength (blue) light at the macula. The AREDS2 study concluded that supplementation of L and Z is beneficial for patients with non-advanced age-related macular degeneration (AMD). The CREST and other studies had reported that dietary supplementation of these carotenoids could enhance contrast sensitivity among the Caucasian population, whereas little information is known about the effect of dietary supplementation of carotenoids on contrast sensitivity among Chinese. Thus in this study, we aim to investigate whether supplementation of a formulation containing 10 mg L, 10 mg MZ, and 2mg Z on contrast sensitivity in Chinese subjects free of retinal disease. This study is a single-center, double-blinded, placebo-controlled, randomized clinical trial conducted at Zhongshan Ophthalmic Center (ZOC), Sun Yat-sen University, Guangzhou, China. Participants in the intervention group received oral supplementation of 10 mg L, 10 mg MZ, and 2mg Z in a formula base oil suspension as one soft gel capsule in the morning per day. Participants in the control group receive one soft gel capsule of placebo oil per day. The intervention and placebo supplements are identical in external appearance, and the two treatments are therefore indistinguishable from each other. The duration of the study intervention is 12 months, and study visits are conducted at baseline, 3 months, 6 months, and 12 months. The primary outcome measure is the change in contrast sensitivity (CS) at 6 cycles per degree (cpd) over the study course: Y=CS4-CS1, where CS1 is CS at 6 cpd at baseline, CS4 is the CS at 6cpd at the 12-month follow-up. The secondary outcomes of this study include CS at other cpds and at other study visits, best-corrected visual acuity, subjective visual function, and skin carotenoid levels at each study visit.

02

Conditions studied

  • Vision Disorders

Browse trials for

03

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Chinese subjects
  • Age 35 years or above
  • Monocular BCVA of 6/6 or better
  • No more than +/- 5 diopters spherical equivalence of refraction
  • No previous consumption of supplements containing macular carotenoids (L, Z and/or MZ) within the last 12 months
  • Without severe retinal diseases (eg. retinal detachment, glaucoma, macular hole, idiopathic epiretinal membrane, retinitis pigmentosa, and age-related macular degeneration (assessed by experienced ophthalmologists during ocular examination)

Exclusion criteria

Exclusion Criteria:

  • Unable to provide informed consent
  • With diagnosed diabetes
  • With severe systemic disease which affects physical mobility and successful follow-up
  • Contrast sensitivity at a spatial density of 6 cpd ≤ 1.5 % at baseline in the eye with better visual acuity
  • Subjects who plan to receive cataract surgery within the next year
  • Subjects who are unable to cooperate with the examinations during follow-ups, such as those who suffer from other serious systemic diseases or mental abnormalities
  • History of intraocular surgery (eg. cataract surgery, vitrectomy and retinal laser photocoagulation)
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Carotenoids group

    Participants in the intervention group receive oral supplementation of 10 mg L, 10 mg MZ and 2mg Z in a formula base oil suspension as one soft gel capsule in the morning per day. Each capsule contains 22 mg of carotenoids (10+10+2mg), thus each participant in the intervention group will receive a total of 22 mg of carotenoids per day.

    Dietary Supplement: Carotenoids supplementation

  • Placebo comparator
    Placebo group

    Participants in the control group receive one soft gel capsule of placebo oil per day.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementCarotenoids supplementation

    Daily oral supplementation of a soft gel capsule containing 10mg lutein (L), 10mg meso-zeaxanthin (MZ) and 2mg zeaxanthin (Z).

  • Dietary supplementPlacebo

    Daily oral supplementation of a soft gel capsule containing only placebo oil

05

What researchers measure

Primary outcomes

  1. Change in contrast sensitivity (CS) at 6 cycles per degree (cpd) over 1 year

    CS at 6 cpd at the 12-month follow-up minus CS at 6 cpd at baseline.

    Time frame: 1 year

Secondary outcomes

  1. CS at other cpds and at other study visits

    CS at 1.2, 2.4, 9.6 and 15.15 cpd at baseline, 3-month follow-up, 6-month follow-up and 12-month follow-up; as well as CS at 6 cpd at 3-month follow-up and 6-month follow-up

    Time frame: 1 year

  2. Best-corrected visual acuity

    Best-corrected visual acuity at baseline, 3-month follow-up, 6-month follow-up and 12-month follow-up

    Time frame: 1 year

  3. Subjective visual function

    Subjective visual function measured by questionnaire at baseline, 3-month follow-up, 6-month follow-up and 12-month follow-up

    Time frame: 1 year

  4. Skin carotenoids score

    Skin carotenoids score at baseline, 3-month follow-up, 6-month follow-up and 12-month follow-up

    Time frame: 1 year

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Xu K, Tang X, Zhang Y, Tay JP, Zhang S, Qin Y, Wong W, He M, Han X. Effect of carotenoids supplementation on visual function in Chinese adults free of retinal disease: protocol for the CSV double-blind, randomised, placebo-controlled trial. BMJ Open. 2026 Mar 26;16(3):e112364. doi: 10.1136/bmjopen-2025-112364. PubMed 41887628 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT06098677
Lead sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Collaborators
Blackmores (China) CO., Ltd
Responsible party
Xiaotong Han (Professor, Zhongshan Ophthalmic Center, Sun Yat-sen University) — Principal investigator
First posted
Oct 24, 2023
Start date
May 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 23, 2026

Study contacts

Xiaotong Han, PhD
Contact
hanxiaotong2@gzzoc.com
81-020-6660-4125

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion